| abstract |
This refers to compounds corresponding to formula (1), as well as to the procedures for preparing them and their therapeutic use and to medications based on the compound. Claim 1: Compound corresponding to formula (1) wherein: R¹ represents: -C₁₋₄ alkyl; -haloalkyl C₁₋₄; R² represents: a group of formula (2); a group of formula (3); a group: -A-X; R³ represents: -H; halogen; -C₁₋₆ alkyl; a cyano group; -CO₂H; -CONH₂; A represents: an aryl or heteroaryl group; X is absent or represents: halogen, a cyano group, an oxo group, - (CH₂) ₙOH, -C₁₋₆ haloalkyl, -C₁₋₆ alkyl, -C₁₋₆ alkoxy, - (CH₂) ₙ-aryl, -CHOH -aryl, heterocycle, heteroaryl, -C₁₋₆-heterocycle alkyl, -C₁₋₆-heteroaryl alkyl, -C₁₋₆-COORᵃ alkyl, -C₁₋₆-NRᵃRᵇ alkyl, -heteroaryl- (CH₂) ₙ-NRᵃRᵇ, - (CH₂) ₙ-NRᵃ-C (O) -Rᵇ, -NRᵃRᵇ, -NRᵃ- (CH₂) ₙ-O-Rᵇ, -NRᵃ-heterocycle, -NRᵃ-aryl, -NRᵃ-C (O) - (CH₂) ₙ-NRᵃRᵇ, -NRᵃ-C (O) -aryl, -NRᵃC (O) -C₁₋₆ alkyl, -NRᵃ-C (O) -C₁₋₆-aryl alkyl, -NRᵃ-C (O) - (CH₂ ) ₙ-O-Rᵇ, -NRᵃ-SO₂- (CH₂) ₙ-aryl, -NRᵃ-SO₂- (CH₂) ₙ-NRᵃRᵇ, -NRᵃ-SO₂-Rᵇ, -NRᵃ-SO₂-aril-O-aryl, - NRᵃ-SO₂-aril- (CH₂) ₙ-NRᵇ-C (O) -Rᵇ, -COORᵃ, -CONRᵃRᵇ, -C (O) -NRᵃ- (CH₂) ₙ-O-Rᵇ, -C (O) -NRᵃ -aryl-C (O) -NRᵃRᵇ, -C (O) -NRᵃ- (CH₂) ₙ-NRᵃRᵇ, -C (O) -NRᵃ- (CH₂) ₙ-heteroaryl, -O- (CH₂) ₙ-NRᵃRᵇ, -O-heterocycle, -CO-heterocycle, -CO-het eroaryl, -SO₂NRᵃRᵇ, -SO₂-heterocycle; Rᵃ and Rᵇ independently represent: -H, -C₁₋₆ alkyl; n represents 0, 1, 2 or 3; in the form of the base or of an acid addition salt, and also in the form of hydrate. |